Skip to Main Content

Paper Details

The ectonucleotidase CD39 identifies tumor-reactive CD8<sup>+</sup> T cells predictive of immune checkpoint blockade efficacy in human lung cancer.
Immunity
19
2023
CD39, CD39 CD8 T cells, CD8, CD8 T cells, PD-L1, anti-tumor T cells, cancer, driver, ectonucleotidase, human, lung cancer, non-small cell, programmed death-ligand 1, tumor, tumor-reactive CD8 T cells
Author NameAffiliation
Andrew ChowMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College
Hira RizviDruckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center
Elisa de StanchinaMemorial Sloan Kettering Cancer Center
Charles M RudinMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College, USA Druckenmiler Center for Lung Cancer Research
  • 1 - 4

Datasets

Release 1.2